TRex Bio (NASDAQ:TRXB) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of TRex Bio (NASDAQ:TRXB) in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm issued an overweight rating and a $20.00 price target on the stock.

Separately, Wedbush initiated coverage on shares of TRex Bio in a report on Monday. They set an “outperform” rating and a $30.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $29.67.

TRex Bio Trading Down 4.1%

TRXB opened at $12.99 on Tuesday. TRex Bio has a twelve month low of $12.50 and a twelve month high of $16.56.

Insider Buying and Selling

In other TRex Bio news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the transaction, the insider directly owned 1,346,501 shares in the company, valued at approximately $18,851,014. The trade was a 15.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.